Skip to main content
OpenTrials
Completed

NCT Number: NCT06094582

Knowledges and Use of Cannabidiol in Older Adults

The use of non-medical cannabidiol (CBD) has been growing recently in France and in the world, in young but also older adults. Few data are available on the use of cannabidiol in older adults. A better knowledge of the use of cannabidiol in older adults, and of their own knowledges of the molecule, is necessary to guide and follow the CBD uptake in this population and avoid potential adverse events.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Aging Frailty Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

65 year–120 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Toulouse

Toulouse, 31059, France

About this study

Cannabidiol may be used by patients because it may have beneficial pharmacological effects (including anxiolytic, analgesic, anti-inflammatories or antioxidant effects). Older adults aged 65 years and over, are more frequently at risk of multimorbidity and loss of autonomy, and may present with several symptoms like pain, anxiety, sleep disturbances, that may potentially respond to CBD. The molecule is often marketed as devoid of adverse effects. Nevertheless, with ageing, reduction in liver and kidney function, may have an impact on the metabolism and elimination of CBD and increase the risk of side-effect. As well, the risk of interaction with drugs frequently prescribed in older adults such as CYP3A4 inhibitors (verapamil, ketoconazole …), CYP3A4 inducers (phenytoin, carbamazepine, …) or CY92C19 inhibitors or inducers (fluoxetine …), may increase the risk of side effects. Our hypothesis is that the use of CBD has increased last years in older adults, but that they are insufficiently informed about this molecule. There is a need to assess the prevalence of CBD use in older adults in France, to assess the knowledges of CBD users about this substance, and to better characterize CBD users.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • admitted to the frailty clinic, in Toulouse University Hospital during the recruitment period.

Exclusion criteria

  • major cognitive disorder with Mini Mental State Examination <20
  • being under legal supervision or guardianship.

Treatment and study plan

Questionnaire

Other

Participants will have to fulfill a short questionnaire (10 minutes) concerning their use and knowledges about CBD.

Primary outcomes

  1. Prevalence of CBD use (having consumed CBD at least once)

    Time frame: 1 day

    The patient will complete a questionnaire about CBD use

Sponsors and collaborators

Lead sponsor

University Hospital, Toulouse

Other

Registry information

Official study title

Knowledges and Use of Cannabidiol in Older Adults Aged 65 Years and Over in France

Acronym: CBD-65

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Oct 23, 2023
Registry last updated
Dec 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.